BioSpace News Archive

Tessera Therapeutics, the biotechnology company pioneering GENE WRITING™ technology, today announced the appointment of Anne-Virginie Eggimann, M.Sc. as Chief Regulatory Officer (CRO) responsible for leading U.S. and global regulatory science and program.

Glaukos Corporation today announced that its management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 7, 2022, at 3:45 p.m. ET in Boston, MA.

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will host an Investor Day on Sept. 20, 2022.

Repligen Corporation today announced that it will host “Repligen Investor Day 2022” on Tuesday, September 20. The live event will take place at the Nasdaq MarketSite in New York City from 8:20 to 11:30 a.m. EDT.

Think Research Corporation today announced that it will release its financial results for the three months ended June 30, 2022 before the market opens on August 29, 2022.

Ayala Pharmaceuticals, Inc. announced that data on the efficacy and tolerability of investigational new drug AL102 from Part A of the Phase 2/3 RINGSIDE study will be presented in an oral presentation at the European Society for Medical Oncology Congress, to take place September 8-13, 2022 in Paris, France.

Daré Bioscience, Inc. today announced that it has entered into a license agreement with Hennepin Life Sciences LLC under which Daré acquired the exclusive global rights to develop and commercialize treatments delivering the novel antimicrobial glycerol monolaurate (GML) intravaginally for a variety of vaginal health conditions including bacterial, fungal, and viral infections.

CymaBay Therapeutics, Inc. today announced that management will participate in a mini symposium on primary biliary cholangitis (PBC) hosted by B. Riley Securities on Wednesday, August 24.

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced top-line data at 24 months showing increased effects over time with intravitreal pegcetacoplan, an investigational, targeted C3 therapy, in the Phase 3 DERBY and OAKS studies in geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

PerkinElmer Inc. today announced that the Company will present at the 2022 Wells Fargo Healthcare Conference and the Baird’s 2022 Global Healthcare Conference.